Abstract

The study was investigated to find out the impact of the Biofield Energy Treated test formulation on the function of vital

organs viz. bones, heart, liver, lungs, and brain in various cell-based assays. The test formulation and the cell media was

divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a

renowned Biofield Energy Healer, Inthirani Arul, Canada and was labeled as the Biofield Energy Treated (BT) test

formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in nature in six different

cells. The Biofield Energy Treated medium (BT-Med) + untreated test item (UT-TI) group showed 97.9% and 88.9%

restoration of cell viability at 10 and 25 μg/mL, respectively as compared to the UT-Med + UT-TI group in human cardiac

fibroblasts cells (HCF). Moreover, BT-Med + BT-TI group showed 62.8% and 86.2% restoration of cell viability at 1 and

63 μg/mL, respectively in human hepatoma cells (HepG2) compared to untreated. Furthermore, 125.6% (at 0.1 μg/mL)

and 94.8% (at 63 μg/mL) restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial

cells (A549) by UT-Med + BT-TI and BT-Med + UT-TI groups, respectively compared to the untreated.

The alkaline phosphatase (ALP) level was significantly increased by 81.8%, 83.9%, and 83.2% in the UT-Med + BT-TI, BTMed

+ UT-TI, and BT-Med + BT-TI groups, respectively at 50 μg/mL in human bone osteosarcoma cells (MG-63)

compared to the untreated. Additionally, the level of ALP was significantly increased by 1430% (at 0.1 μg/mL), 332.6%

(at 1 μg/mL), and 265% (at 0.1 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively

in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF

(heart) cells (decreased of LDH activity) was significantly increased by 69% (at 1 μg/mL), 100.9% (at 0.1 μg/mL), and

76.9% (at 25 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to the

untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly

increased by 44.4% (at 0.1 μg/mL), 63.9% (at 10 μg/mL), and 84.9% (at 1 μg/mL) in the UT-Med + BT-TI, BT-Med + UTTI,

and BT-Med + BT-TI groups, respectively compared to untreated in HepG2 cells. The percent protection of A549

(lungs) cells (increased of SOD activity) was significantly increased by 35.1% and 78.3% in the UT-Med + BT-TI and BTMed

+ BT-TI groups, respectively at 1 μg/mL compared to untreated in A549 cells.

Serotonin level was significantly increased by 71.6%, 82.8%, and 104.8% in the BT-Med + BT-TI group at 1, 10, and 25

μg/mL, respectively as compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ)

of vitamin D receptor (VDR) was significantly increased by 253.5% (at 1 μg/mL) and 270.3% (at 50 μg/mL) in the BT Med + BT-TI group; while 235.2% at 10 μg/mL in the BT-Med + UT-TI group as compared to the untreated in MG-63 cells.

Overall, these results suggest that Biofield Treated test formulation significantly improved the relevant bones, heart, liver,

lungs, and brain-related biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can

be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones.

Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as

coronary artery disease, heart attack, heart failure, arrhythmias, congenital heart disease, cirrhosis, cardiomyopathy,

liver cancer, Wilson disease, hemochromatosis, pneumonia, asthma, chronic bronchitis, emphysema, osteoporosis, cystic

fibrosis, etc.